Medipost Co Ltd
Company Profile
Business description
Medipost Co Ltd is a Korea-based stem cell biotechnology company. The company is engaged in developing products to meet unmet medical needs. The company operates its business through four distinct segments: Stem Cell Therapeutics, Cord Blood Bank, Cosmetics, and Health Supplements. The Cord Blood Bank Division is involved in collecting and storing stem cells from the newborn's umbilical cord. The Stem Cell Therapeutics division manufactures allogeneic stem cell drug products. The Health Supplements division offers vitamins and nutritional supplements. The Cosmetics division is involved in the sales and marketing of natural cosmetics.
Contact
21, Daewangpangyo-ro 644
Bundang-gu
Gyeonggi-do
Seongnam
KORT: +82 234656650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
604
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
stocks
Why Guzman and Reece's share reversals have a lot in common
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,477.30 | 20.70 | -0.24% |
CAC 40 | 8,137.26 | 86.19 | 1.07% |
DAX 40 | 22,732.24 | 321.97 | 1.44% |
Dow JONES (US) | 43,758.96 | 137.80 | 0.32% |
FTSE 100 | 8,722.03 | 53.36 | 0.62% |
HKSE | 23,787.93 | 753.91 | 3.27% |
NASDAQ | 19,196.80 | 170.41 | 0.90% |
Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
S&P 500 | 5,991.45 | 36.20 | 0.61% |
S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
SSE Composite Index | 3,380.21 | 34.17 | 1.02% |